Stockwatch: A Brief History Of Asset Swaps
This article was originally published in Scrip
Even with the proposed acquisition of Allergan Plc by Pfizer Inc., 2015 was not so much the year of life science M&A or even the bursting of the biotech bubble but the rise in the asset-swapping imperative. The jury is almost certainly still out for this development amongst big pharmaceutical companies so unlike the pharmaceutical mega-merger there is at least one reason why we may continue to see asset swap transactions in 2016.
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.